Radiopharmaceutical developer Molecular Insight Pharmaceuticals of Cambridge, MA, has completed a phase II clinical trial for its chest imaging agent Zemiva, the company announced.
The trial enrolled 510 patients over 14 months at 50 hospitals throughout North America. It was initiated in May 2007 to assess the ability of Zemiva to detect cardiac ischemia in the emergency department setting.
The trial found that when combined with the standard of care for the diagnostic evaluation of the chest pain patient, Zemiva improved the detection of cardiac ischemia by more than 50%, Molecular Insight said.
Zemiva is a fatty acid analog also known as 123I-BMIPP or iodofiltic acid I 123 that detects cardiac ischemia by revealing abnormalities in the fatty acid metabolism of the heart. Zemiva can be imaged using standard nuclear medicine cameras.
Related Reading
Molecular Insight reports Q3 financials, November 13, 2008
Molecular Insight reports positive trial results, November 10, 2008
Molecular Insight installs interim CEO, September 26, 2008
Molecular Insight touts Trofex studies, June 18, 2008
Molecular Insight starts Trofex trial, June 12, 2008
Copyright © 2008 AuntMinnie.com
